Myovant Sciences

Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie
Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie
Fierce Pharma
Myovant Sciences
Pfizer
FDA
Relugolix
uterine fibroids
Flag link:
Corporate and regulatory developments over the holidays
Corporate and regulatory developments over the holidays
EP Vantage
AstraZeneca
Bristol-Myers Squibb
Celltrion
Cullinan Oncology
JNJ
Myovant Sciences
Osmotica Pharmaceuticals
Pfizer
Y-mAbs Therapeutics
United Therapeutics
Zai Lab
Flag link:
In groundbreaking move, FDA approves Myovant's relugolix as the first once-a-day pill for advanced prostate cancer
In groundbreaking move, FDA approves Myovant's relugolix as the first once-a-day pill for advanced prostate cancer
Endpoints
Myovant Sciences
Relugolix
FDA
prostate cancer
Orgovyx
Flag link:
Myovant Squares Off with AbbVie On Endometriosis Treatment
Myovant Squares Off with AbbVie On Endometriosis Treatment
Motley Fool
Myovant Sciences
AbbVie
endometriosis
Relugolix
Orilissa
clinical trials
Flag link:
Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study
Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study
Motley Fool
Myovant Sciences
Relugolix
uterine fibroids
clinical trials
Flag link:
Is Myovant's New Prostate Cancer Drug a Game Changer?
Is Myovant's New Prostate Cancer Drug a Game Changer?
Motley Fool
Myovant Sciences
prostate cancer
clinical trials
Relugolix
Flag link:
Myovant to submit lead drug for prostate cancer approval after Phase 3 results
Myovant to submit lead drug for prostate cancer approval after Phase 3 results
Biopharma Dive
Myovant Sciences
prostate cancer
clinical trials
Relugolix
Flag link:
Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown
Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown
Fierce Biotech
Myovant Sciences
Relugolix
clinical trials
uterine fibroids
AbbVie
Elagolix
Flag link:
Drugmakers revive R&D focus on long stagnant women's health market
Drugmakers revive R&D focus on long stagnant women's health market
Medical Marketing and Media
R&D
Women's Health
innovation
Myovant Sciences
Amgen
UCB Pharma
breast cancer
Pfizer
S1 Biopharma
Ibrance
Addyi
Flag link: